Research programme: monoclonal antibody therapeutics - Agenus

Drug Profile

Research programme: monoclonal antibody therapeutics - Agenus

Alternative Names: AGEN 2041; Checkpoint modulator antibodies - 4-Antibody/Ludwig Institute for Cancer Research; Checkpoint modulator antibodies - Agenus/Incyte; CPM antibodies - Agenus/Incyte; Cytotoxic T-lymphocyte antigen 4 inhibitor antibodies - Agenus/Recepta; PDCD 1 protein inhibitor antibodies - Agenus/Recepta

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 4-Antibody; Ludwig Institute for Cancer Research
  • Developer Agenus; Ludwig Institute for Cancer Research
  • Class Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; HAVCR2 protein inhibitors; OX40 receptor agonists; PDCD 1 protein inhibitors; TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Feb 2017 Incyte and Agenus amend licensing agreement from profit-sharing agreement to royalty bearing agreement
  • 29 Jul 2016 Agenus plans a clinical trial of AGEN 2041 for Cancer in USA
  • 05 Mar 2014 Preclinical trials in Cancer in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top